HK Stock Market Move | IMMUNEONCO-B(01541) soars over 17%, clinical value of CD47 double antibody supported by the "Science" magazine

IMMUNEONCO-B(01541) surged over 17%, rising by 17.09% to 5.55 Hong Kong dollars as of press time, with a trading volume of 11.4379 million Hong Kong dollars. On the news front, the Medical Cube article pointed out that a recent paper in Science magazine coincides with Yimengang's thinking on the development of target drugs. The clinical data of IMM0306 powerfully proves that as long as the drug is designed properly, it can simultaneously solve the low efficacy problem of "antigen sink" and provide "dual signals" for synergistic activation, indicating that the CD47 target still has huge clinical development value. Guoyuan International previously pointed out that the company's research and development pipeline is continuously enriched, and its risk resistance ability is enhanced. The clinical efficacy data of CD47CD20 dual antibody (IMM0306) is excellent, and it is expected to become a heavyweight drug in the field of immune-mediated diseases. The company is a global leader in CD47 fusion protein innovation, with a rich pipeline and broad application prospects in the fields of oncology, immune-mediated diseases, and cardiovascular diseases.